A Study of IAP0971 in Combination With Bacillus Calmette Guerin in High Risk Non-muscular Invasive Bladder Cancer
NCT06255964 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 236
Last updated 2024-02-13
Summary
The efficacy and safety of IAP0971 single drug or combined with BCG intravesical instillation in the treatment of high-risk non muscle invasive bladder cancer with BCG treatment failure.
Conditions
Interventions
- DRUG
-
IAP0971
Induction period (6 weeks): IAP0971 single drug bladder infusion, once a week;Maintenance period: IAP0971 single drug bladder infusion, performed at 3, 6, 12, 18, and 24 months, once a week, for 3 consecutive times
- COMBINATION_PRODUCT
-
IAP0971+BCG
Induction period (6 weeks): IAP0971 combined with BCG,Bladder perfusion, once a week;Maintenance period: IAP0971 combined with BCG bladder perfusion,Maintain at months 3, 6, 12, 18, and 24Perfusion, once a week, three times in a row.
- COMBINATION_PRODUCT
-
IAP0971+BCG
Induction period (6 weeks): IAP0971 combined with BCG,Bladder perfusion, once a week;Maintenance period: IAP0971 combined with BCG bladder irrigationNote, progress at months 3, 6, 12, 18, and 24Perform maintenance perfusion once a week, three times in a row.
Sponsors & Collaborators
-
SUNHO(China)BioPharmaceutical CO., Ltd.
lead INDUSTRY
Principal Investigators
-
ye dingwei, M.D. · Cancer Hospital affiliated to Fudan University
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SEQUENTIAL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-02-15
- Primary Completion
- 2024-10-07
- Completion
- 2026-12-07
- FDA Drug
- Yes
More Related Trials
-
Phase I Mitomycin Combined With Bacillus Calmette-Guérin (BCG) for Bladder Cancer
NCT02311101 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC
NCT06186414 ·Status: RECRUITING ·Phase: PHASE1
-
Clinical Study of T3011 Intravesical Instillation for Treatment of NMIBC Patients
NCT06427291 ·Status: RECRUITING ·Phase: PHASE1
-
Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma
NCT00794950 ·Status: COMPLETED ·Phase: PHASE2
-
Bacillus of Calmette and Guerin (BCG) Versus Gemcitabine For Intravesical Therapy In High Risk Superficial Bladder Cancer
NCT00696579 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of SHR-1501 Alone or in Combination With BCG or SHR-1316 in Subjects With NMIBC
NCT05410730 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder
NCT03519256 ·Status: TERMINATED ·Phase: PHASE2
-
Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer
NCT06441110 ·Status: RECRUITING ·Phase: PHASE3
-
BCG for Therapeutic Use Phase I Clinical Trial
NCT06100653 ·Status: COMPLETED ·Phase: PHASE1
-
Combined Use of BCG and Interferon Alpha in Bladder Cancer
NCT00330707 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer
NCT06187506 ·Status: RECRUITING ·Phase: PHASE2
-
Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment
NCT04179162 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Bladder PREserVation by RadioTherapy and Immunotherapy in BCG Unresponsive Non-muscle Invasive Bladder Cancer
NCT03950362 ·Status: UNKNOWN ·Phase: PHASE2
-
A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer
NCT05327647 ·Status: RECRUITING ·Phase: PHASE2
-
BCG for Therapeutic Use Phase Ⅲ Clinical Trial
NCT06747455 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer
NCT07122414 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)
NCT04149574 ·Status: TERMINATED ·Phase: PHASE3
-
Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]
NCT03504163 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Safety and Efficacy of BCG Combined With Tislelizumab for BCG-untreated Patients With High-risk Non-muscle Invasive Bladder Cancer
NCT05580354 ·Status: UNKNOWN ·Phase: PHASE4
-
Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin
NCT04387461 ·Status: COMPLETED ·Phase: PHASE2
-
Novel Peptide Vaccination for Patients With Advanced Bladder Cancer
NCT00635336 ·Status: COMPLETED ·Phase: PHASE1
-
Can We Predict of the Response of High Risk Non Muscle Invasive Bladder Cancer Patients to Intravesical Bacillus Calmette-Guerin? The Role of Immunological Markers
NCT04723121 ·Status: COMPLETED ·Phase: NA
-
Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC
NCT04630730 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Peptide Vaccine Focusing on Prevention of the Recurrence for Bladder Cancer
NCT00633204 ·Status: UNKNOWN ·Phase: PHASE2
-
Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment
NCT04706598 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2